Vanadium Compositions Targeting SLC26A2-Positive Cancer Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for advanced solid tumors, such as sarcomas and carcinomas, lack precision in selectively killing neoplastic cells characterized by specific molecular traits, particularly those with high expression of SLC26A2, rendering them largely incurable.
Innovation Solution
Utilization of vanadium-containing drugs, such as bis(maltolato)oxovanadium(IV) (BMOV), bis(ethylmaltolato)oxovanadium(IV) (BEOV), and bis(isopropylmaltolato)oxovanadium(IV) (BIOV), which target SLC26A2-positive cancers, including ovarian, endometrial, brain, bone, and lung cancers, as identified through genomic screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional treatments are used for advanced solid tumors, then broad coverage of tumor types is achieved, but precision in selectively killing neoplastic cells with specific molecular traits is poor
Solution Approach 1:
The patent applies local quality by designing a treatment approach that tailors therapy to the specific molecular characteristics of individual tumors. Vanadium-containing compounds are selected based on the presence of SLC26A2 overexpression, creating a localized, precision treatment strategy rather than uniform treatment across all tumor types. This allows high precision for SLC26A2-positive tumors while maintaining adaptability to other tumor types through alternative treatment options.
Solution Approach 2:
The patent utilizes parameter changes by identifying SLC26A2 expression levels as a key parameter for treatment selection. By measuring and responding to this molecular parameter, the system achieves precision targeting. The vanadium-containing compounds specifically interact with cells exhibiting this parameter change (overexpression), enabling selective killing while preserving normal cells and other tumor types lacking this parameter.
2Measurement precision
If vanadium-containing drugs are used to target SLC26A2-positive cancers, then precision killing of neoplastic cells is enhanced, but treatment options for SLC26A2-negative cancers remain limited
Solution Approach 1:
The patent applies segmentation by dividing cancer treatment into distinct pathways based on molecular profiling. SLC26A2-positive cancers are segmented as a specific targetable subgroup receiving vanadium-containing compounds, while other cancers are segmented into alternative treatment categories. This segmentation enables high precision for the targeted subgroup while maintaining overall versatility through multiple treatment pathways.
Solution Approach 2:
The patent implements universality by creating a multi-functional treatment system that can address different cancer types through different mechanisms. The vanadium-containing compounds serve as a specialized tool for SLC26A2-positive cancers, while the overall system maintains universality by incorporating multiple treatment options for other cancer types, making the system adaptable to diverse clinical scenarios.
Data Source
AI summary
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and/or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.